Latest news with #QuarterlyReport
Business Wire
3 days ago
- Business
- Business Wire
Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus' or the 'Company'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has rescheduled the release of its financial results and conference call for the third fiscal quarter ended May 31, 2025, which had previously been scheduled for July 2, 2025. The Company currently expects to issue its third quarter results after market close and hold its conference call on Monday, July 14, 2025, at 5:00 p.m. Eastern Time. Since transitioning from a large accelerated filer to a non-accelerated filer, the Company is using the all of the time allowed by regulation before releasing its third quarter financial results. Simulations Plus is reaffirming the preliminary revenue for its third fiscal quarter and full year 2025 revenue guidance which was previously provided on June 11, 2025. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 million and $80 million The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 15, 2025, the SEC filing deadline. Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results. Third Quarter Fiscal 2025 Webcast and Conference Call Details The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website where it will also be available for replay approximately one hour following the call. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Preliminary Financial Results and Financial Guidance The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP. In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
Yahoo
5 days ago
- Business
- Yahoo
PACS Group to Restate Certain Previously Issued Financial Statements
Audit Committee Investigation Substantially Complete FARMINGTON, Utah, June 16, 2025--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) ("PACS" or the "Company") announced today that it will restate its previously issued condensed combined/consolidated financial statements as of and for the three months ended on March 31, 2024 included in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024 (as amended on May 21, 2024), and as of and for the three and six months ended on June 30, 2024 included in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024 (collectively, the "Prior Financial Statements," and each such quarterly period in the six months ended June 30, 2024, the "Impacted Periods"). The Prior Financial Statements and any previously furnished reports or communications of PACS describing the Company's financial results for the Impacted Periods should no longer be relied upon. As previously disclosed, the Company's independent Audit Committee of the Board of Directors (the "Audit Committee"), with assistance from external counsel, has been conducting an independent investigation of third-party allegations. The Audit Committee has made substantial progress and is nearing the completion of the investigation. To date, the Audit Committee has found no basis to question the integrity of the Company's Executive Vice Chairman, Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer. In connection with additional facts learned, including as a result of the Audit Committee's independent investigation, and due to regulatory, compliance and Medicare Part B billing uncertainties, management has determined that it is appropriate to reconsider the Company's judgmental assessments of the compliance of its respiratory and certain other therapy services. Management has also determined that it is appropriate to reconsider the application of certain aspects of revenue recognition guidance under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts With Customers ("ASC 606") regarding revenue from billings for such services. As a result, the Company believes that the revenue associated with the provision of respiratory services and certain other therapy services billed under Medicare Part B should not have been recognized as revenue in the Impacted Periods. Accordingly, the Company has determined that it overstated total revenue in the condensed combined/consolidated statements for the Impacted Periods by: Approximately $15.0 million to $17.0 million for the three month period ended March 31, 2024 and approximately $46.0 million to $48.0 million for the three month period ended June 30, 2024. These amounts are preliminary and may be subject to change. The Company is working diligently to restate the Prior Financial Statements as soon as practicable. Given the ongoing investigation, PACS has been unable to file its Quarterly Report on Form 10-Q for the nine months ended September 30, 2024, its Annual Report on Form 10-K for the year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the three months ended March 31, 2025. As previously disclosed in the Company's Current Report on Form 8-K filed on June 2, 2025, The New York Stock Exchange ("NYSE") provided the Company with an additional trading period through September 2, 2025, subject to reassessment on an ongoing basis, to file its delinquent filings and regain compliance with NYSE listing standards. PACS intends to restate the Prior Financial Statements and file its delinquent quarterly and annual reports within the granted additional period. Further to the Audit Committee's ongoing investigation, the Company's management team, together with external counsel and outside advisors, has undertaken a thorough review of its regulatory compliance program and has begun to implement additional measures designed to enhance processes and controls surrounding regulatory compliance. As part of this process, PACS has retained a new Interim Chief Compliance Officer to oversee the ongoing review and the implementation of updates to the Company's compliance program. PACS is also continuing to assess the effect of any restatements on the Company's internal controls over financial reporting and its disclosure controls and procedures. Additional information relating to the restatement is available in the Company's Current Report on Form 8-K filed today. About PACS™ PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 314 post-acute care and senior living facilities across 17 states, serving over 30,000 patients daily. References herein to the consolidated "Company," as well as the use of the terms "we," "us," "our," "its" and similar verbiage, refer to PACS Group, Inc. and its consolidated subsidiaries, taken as a whole. PACS Group, Inc. and its subsidiaries that are not licensed healthcare providers do not provide healthcare services to patients, residents or any other person, and do not direct or control the provision of services provided or the operations of those provider subsidiaries. All healthcare services are provided solely by its applicable subsidiaries that are licensed healthcare providers, under the direction and control of licensed healthcare professionals in accordance with applicable law. More information about PACS is available at Forward-Looking Statements This press release contains, and other communications of the Company may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as "believe," "expect," "anticipate," "intend," "estimate," "project," "outlook," "forecast," "target," "trend," "plan," "goal," or other words of comparable meaning or future-tense or conditional verbs such as "may," "will," "should," "would," or "could." Statements concerning the Company's future are forward-looking statements, and are based on management's current expectations, assumptions and beliefs about the Company's business, financial performance, operating results, the industry in which the Company operates and possible future events. These statements include, but are not limited to, statements regarding the Company's expectations regarding the timing of and its ability to restate the Prior Financial Statements and file its delinquent quarterly and annual reports. Forward-looking statements convey the Company's expectations, intentions, or forecasts about future events, circumstances, results, or aspirations. Forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions, which may change over time and many of which are beyond the Company's control, and that could cause the Company's actual results to materially and adversely differ from those expressed in any forward-looking statement, including the outcome of any ongoing government or internal investigations, risks associated with litigation, risks associated with the Company's ability to restate the Prior Financial Statements and file its delinquent quarterly and annual reports within the granted additional period, risks associated with the NYSE's ongoing compliance monitoring, and the other risks described in the Company's filings with the Securities and Exchange Commission. View source version on Contacts Investors: IR@ Media: Brooks StevensonVP Corporate Communication262 N. University AvenueFarmington, UT 84025T:
Business Wire
5 days ago
- Business
- Business Wire
PACS Group to Restate Certain Previously Issued Financial Statements
FARMINGTON, Utah--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) ('PACS' or the 'Company') announced today that it will restate its previously issued condensed combined/consolidated financial statements as of and for the three months ended on March 31, 2024 included in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2024 (as amended on May 21, 2024), and as of and for the three and six months ended on June 30, 2024 included in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024 (collectively, the 'Prior Financial Statements,' and each such quarterly period in the six months ended June 30, 2024, the 'Impacted Periods'). The Prior Financial Statements and any previously furnished reports or communications of PACS describing the Company's financial results for the Impacted Periods should no longer be relied upon. As previously disclosed, the Company's independent Audit Committee of the Board of Directors (the 'Audit Committee'), with assistance from external counsel, has been conducting an independent investigation of third-party allegations. The Audit Committee has made substantial progress and is nearing the completion of the investigation. To date, the Audit Committee has found no basis to question the integrity of the Company's Executive Vice Chairman, Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer. In connection with additional facts learned, including as a result of the Audit Committee's independent investigation, and due to regulatory, compliance and Medicare Part B billing uncertainties, management has determined that it is appropriate to reconsider the Company's judgmental assessments of the compliance of its respiratory and certain other therapy services. Management has also determined that it is appropriate to reconsider the application of certain aspects of revenue recognition guidance under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts With Customers ('ASC 606') regarding revenue from billings for such services. As a result, the Company believes that the revenue associated with the provision of respiratory services and certain other therapy services billed under Medicare Part B should not have been recognized as revenue in the Impacted Periods. Accordingly, the Company has determined that it overstated total revenue in the condensed combined/consolidated statements for the Impacted Periods by: Approximately $15.0 million to $17.0 million for the three month period ended March 31, 2024 and approximately $46.0 million to $48.0 million for the three month period ended June 30, 2024. These amounts are preliminary and may be subject to change. The Company is working diligently to restate the Prior Financial Statements as soon as practicable. Given the ongoing investigation, PACS has been unable to file its Quarterly Report on Form 10-Q for the nine months ended September 30, 2024, its Annual Report on Form 10-K for the year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the three months ended March 31, 2025. As previously disclosed in the Company's Current Report on Form 8-K filed on June 2, 2025, The New York Stock Exchange ('NYSE') provided the Company with an additional trading period through September 2, 2025, subject to reassessment on an ongoing basis, to file its delinquent filings and regain compliance with NYSE listing standards. PACS intends to restate the Prior Financial Statements and file its delinquent quarterly and annual reports within the granted additional period. Further to the Audit Committee's ongoing investigation, the Company's management team, together with external counsel and outside advisors, has undertaken a thorough review of its regulatory compliance program and has begun to implement additional measures designed to enhance processes and controls surrounding regulatory compliance. As part of this process, PACS has retained a new Interim Chief Compliance Officer to oversee the ongoing review and the implementation of updates to the Company's compliance program. PACS is also continuing to assess the effect of any restatements on the Company's internal controls over financial reporting and its disclosure controls and procedures. Additional information relating to the restatement is available in the Company's Current Report on Form 8-K filed today. About PACS™ PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 314 post-acute care and senior living facilities across 17 states, serving over 30,000 patients daily. References herein to the consolidated 'Company,' as well as the use of the terms 'we,' 'us,' 'our,' 'its' and similar verbiage, refer to PACS Group, Inc. and its consolidated subsidiaries, taken as a whole. PACS Group, Inc. and its subsidiaries that are not licensed healthcare providers do not provide healthcare services to patients, residents or any other person, and do not direct or control the provision of services provided or the operations of those provider subsidiaries. All healthcare services are provided solely by its applicable subsidiaries that are licensed healthcare providers, under the direction and control of licensed healthcare professionals in accordance with applicable law. More information about PACS is available at Forward-Looking Statements This press release contains, and other communications of the Company may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project,' 'outlook,' 'forecast,' 'target,' 'trend,' 'plan,' 'goal,' or other words of comparable meaning or future-tense or conditional verbs such as 'may,' 'will,' 'should,' 'would,' or 'could.' Statements concerning the Company's future are forward-looking statements, and are based on management's current expectations, assumptions and beliefs about the Company's business, financial performance, operating results, the industry in which the Company operates and possible future events. These statements include, but are not limited to, statements regarding the Company's expectations regarding the timing of and its ability to restate the Prior Financial Statements and file its delinquent quarterly and annual reports. Forward-looking statements convey the Company's expectations, intentions, or forecasts about future events, circumstances, results, or aspirations. Forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions, which may change over time and many of which are beyond the Company's control, and that could cause the Company's actual results to materially and adversely differ from those expressed in any forward-looking statement, including the outcome of any ongoing government or internal investigations, risks associated with litigation, risks associated with the Company's ability to restate the Prior Financial Statements and file its delinquent quarterly and annual reports within the granted additional period, risks associated with the NYSE's ongoing compliance monitoring, and the other risks described in the Company's filings with the Securities and Exchange Commission.
Business Wire
11-06-2025
- Business
- Business Wire
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus' or the 'Company'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 million and $80 million The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 2, 2025. Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results. 'Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations. 'To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization—transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities. 'These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements. 'Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space,' concluded O'Connor. Third Quarter Fiscal 2025 Press Release, Webcast, and Conference Call Details The Company will report third quarter fiscal 2025 financial results after the market close on Wednesday, July 2, 2025. Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus' performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website where it will also be available for replay approximately one hour following the call. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Preliminary Financial Results and Financial Guidance The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP. In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
Yahoo
11-06-2025
- Business
- Yahoo
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C., June 11, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 million and $80 million The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 2, 2025. Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results. "Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations. "To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization—transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities. "These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements. "Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space," concluded O'Connor. Third Quarter Fiscal 2025 Press Release, Webcast, and Conference Call Details The Company will report third quarter fiscal 2025 financial results after the market close on Wednesday, July 2, 2025. Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus' performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website where it will also be available for replay approximately one hour following the call. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Preliminary Financial Results and Financial Guidance The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP. In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
